Saint Alphonsus Physician Surpasses Procedure Milestone Using Stereotaxis Niobe® ES System
June 14 2016 - 9:00AM
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative
technologies for the treatment of cardiac arrhythmias, and Saint
Alphonsus Health System in Idaho today announced that Dr. Margot
Vloka has completed more than 500 cardiac ablation procedures using
the Niobe® ES remote magnetic navigation system. Dr. Vloka is a
board-certified clinical cardiac electrophysiologist (EP) at the
Saint Alphonsus Stereotaxis lab and a Fellow of the Heart Rhythm
Society.
The Niobe ES system was introduced in the U.S. at the end of
2011 and installed the following year at Saint Alphonsus Health
System, making it the first provider in Idaho to utilize remote
magnetic navigation for ablation procedures. Having experience with
the Niobe system while at the Wisconsin Heart Hospital, Dr. Vloka
was a vocal proponent of the technology when arriving at Saint
Alphonsus in late 2014. After training on the latest generation
Niobe ES system with the aid of the Company’s best practices
program, Dr. Vloka quickly adopted the Niobe ES system as part of
her daily clinical routine for the treatment of atrial arrhythmias,
ventricular tachycardia, congenital heart disease and other complex
cardiac conditions.
“I have always been a ‘belt and suspenders’ type physician,
especially given the delicacy of the cardiovascular system, and
with the Niobe system, I have complete peace of mind that I am
providing the safest approach to cardiac ablation,” said Dr. Vloka.
“The Niobe system’s remote, computer-assisted features reduce risk
of complications and enable me to create more effective lesions
with shorter procedure times than traditional manual and mechanical
therapies. As a result, I am able to complete multiple complex
procedures each day and, most importantly, my patients are able to
resume normal activities with freedom from debilitating
arrhythmias.”
Tom Reinhardt, Assistant Vice President for Saint Alphonsus
Health System, said “We are very pleased to be the only healthcare
provider in the state to offer this groundbreaking treatment for
cardiac ablations. The level of expertise Dr. Vloka has achieved
with Stereotaxis technologies continues to raise the bar for EP
professionals in the region. The Niobe system and its suite of
automations has been a strong addition to the Saint Alphonsus
cardiology services line, expanding our capabilities to better
serve patients across the region.”
About Saint Alphonsus Health System As a
faith-based Catholic ministry and not-for-profit health system,
Saint Alphonsus Health System reinvests in the communities we
serve, through charity care and other benefits. Our goal is to
improve the health and well-being of people by emphasizing care
that is patient-centered, physician-led, innovative and
community-based. Saint Alphonsus Health System serves the people of
southwestern Idaho, eastern Oregon and northern Nevada through
these facilities: Saint Alphonsus Regional Medical Center - Boise,
ID; Saint Alphonsus Medical Center - Nampa, ID; Saint Alphonsus
Medical Center - Ontario, OR; Saint Alphonsus Medical Center -
Baker City, OR; and, Saint Alphonsus Medical Group with primary and
specialty care providers at over 60 clinic locations, all of which
are members of the Saint Alphonsus Health Alliance, a network of
over 1900 employed and independent providers. Saint Alphonsus is a
proud affiliate of Trinity Health, one of the largest
multi-institutional Catholic health care delivery systems in the
nation. Trinity Health serves people and communities in 21 states
from coast to coast with 88 hospitals and 126 continuing care
facilities, home health and hospice programs, and PACE center
locations that provide more than 2.5 million visits annually. To
find out more go to: www.saintalphonsus.org.
About StereotaxisStereotaxis is a healthcare
technology and innovation leader in the development of robotic
cardiology instrument navigation systems designed to enhance the
treatment of arrhythmias and coronary disease, as well as
information management solutions for the interventional lab. Over
100 issued patents support the Stereotaxis platform, which helps
physicians around the world provide unsurpassed patient care with
robotic precision and safety, improved lab efficiency and
productivity, and enhanced integration of procedural information.
Stereotaxis' core Epoch® Solution includes the Niobe® magnetic
navigation system, the Odyssey® portfolio of lab optimization,
networking and patient information management solutions, and the
Vdrive® robotic navigation system and consumables.
The core components of Stereotaxis’ systems have received
regulatory clearance in the United States, European Union, Canada,
China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator,
V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter
advancement system have received clearance in the United States,
Canada, and the European Union. For more information, please visit
www.stereotaxis.com.
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words
"believe”, "estimate”, "project”, "expect" or similar expressions.
Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to, the
Company's ability to raise additional capital on a timely basis and
on terms that are acceptable, its continued listing on the NASDAQ
Capital Market, its ability to continue to manage expenses and cash
burn rate at sustainable levels, its ability to continue to work
with lenders to extend, repay or refinance indebtedness on
acceptable terms, continued acceptance of the Company's products in
the marketplace, the effect of global economic conditions on the
ability and willingness of customers to purchase its systems and
the timing of such purchases, competitive factors, changes
resulting from the recently enacted healthcare reform in the United
States, including changes in government reimbursement procedures,
dependence upon third-party vendors, timing of regulatory
approvals, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments in any particular period or at all because some
of these purchase orders and other commitments are subject to
contingencies that are outside of the Company's control. In
addition, these orders and commitments may be revised, modified,
delayed or canceled, either by their express terms, as a result of
negotiations, or by overall project changes or delays.
Company Contact:
Martin C. Stammer
Chief Financial Officer
314-678-6155
Investor Contact:
Todd Kehrli / Jim Byers
MKR Group, Inc.
323-468-2300
stxs@mkr-group.com